Clinical and coronary outcomes
| Primary adjunctive corticosteroids n=48 | Historical controls n=162 | P value | |
| Treatment resistance | 2/46 (4%)* | 35/118 (30%) | <0.001 |
| Maximum z-score over follow-up | 3.1 (2.5, 5.8) | 3.0 (1.9, 4.4) | 0.26 |
| CAA regression rate | 31/44 (70%) | 108/162 (67%) | 0.72 |
| Maximum z-score over follow-up | 0.11 | ||
| <5.0 | 34 (71%) | 136 (84%) | |
| 5.0 to 9.99 | 8 (17%) | 15 (9%) | |
| ≥10.0 | 6 (12%) | 11 (7%) | |
| Progression in CAA size† | 2 (4%) | 8 (5%) | 1.0 |
| Change in z-score baseline to last follow-up | −2.4 (−3.5 to −1.1) | −1.6 (−2.4 to −0.9) | 0.03 |
| Decrease in z-score by ≥2 units | 28 (58%) | 55 (34%) | 0.004 |
| Laboratories at 1 week post-IVIG | n=47 | n=77 | |
| CRP (mg/dL) | 0.2 (0.1, 0.3) | 0.5 (0.2, 1.1) | <0.001 |
| WBC (1000 cells/µL) | 17.1 (12.7 to 24.6) | 11.0 (8.7 to 13.7) | <0.001 |
| Absolute neutrophil count (1000 cells/µL) | 10.4 (6.2 to 16.5) | 4.4 (2.7 to 7.2) | 0.001 |
| Haematocrit (%) | 33.2 (31.3 to 37.0) | 31.6 (28.4 to 34.1) | 0.013 |
| Platelet count (1000 cells/µL) | 669 (558 to 861) | 731 (543 to 900) | 0.74 |
*Two patients were excluded due to receiving second for treatment of Kawasaki shock syndrome prior to 36 hours post first IVIG.
†Defined as ≥2 unit increase in z-score from baseline to maximal z-score for either left anterior descending coronary artery or right coronary artery.
CAA, coronary artery aneurysm; CRP, C reactive protein; IVIG, intravenous immunoglobulin; WBC, white blood cell.